Results 131 to 140 of about 8,219 (198)

Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study. [PDF]

Dermatol Ther (Heidelb)
Prajapati VH, Jain V, Gooderham MJ, Cecchini M, Lee JK, Lynde CW, Grewal P, Ferrier A, Préfontaine D, Sterling C, Chih-Ho Hong H.   +10 more
europepmc   +1 more source

Pemphigus Erythematosus Treated with JAK1 Inhibitor Upadacitinib: A Case Report and Brief Literature Review. [PDF]

Clin Cosmet Investig Dermatol
Lo HM, Song XR, Zhang Q, Su J, Li WW, Li DM, Wang WH.   +6 more
europepmc   +1 more source

Efficacy and tolerability of janus kinase inhibition strategies for moderate-to-severe Crohn's disease: A systematic review and bayesian network meta-analysis. [PDF]

Ther Adv Gastroenterol
Wazir HU, Mehta K, Shabbir MS, Islam MR, Maaz M, Muzaffar M, Ehsan N, Aliha S, Chauhan A, Khurram A, Saffouri G.   +10 more
europepmc   +1 more source

Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients. [PDF]

Int J Rheum Dis
Meng F, Zhang Y, Chen Y, Lin Z, Li C, Hou X, Wu Y.   +6 more
europepmc   +1 more source

Multicentre, prospective, observational study on the effectiveness and safety of upadacitinib for active perianal fistulising Crohn's disease in patients with prior anti-tumour necrosis factor failure: a study protocol. [PDF]

BMJ Open
Lu C, Xu D, Qian K, Dou L, Ding Y, Fa J, Lin C, Liu X, Huang C, Zeng Y, Yao Y, Wang Q, Wu Y, Wang R, Cao D, Zhang Y, Cao Z, Cui Z.   +17 more
europepmc   +1 more source

Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2. [PDF]

RMD Open
Coates LC, Mease P, Kavanaugh A, Merola JF, Magrey M, Iyile T, Zhou L, Novelli L, Lagunes I, Setty AR, Van den Bosch F.   +10 more
europepmc   +1 more source

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies. [PDF]

J Gastroenterol Hepatol
Wei SC, Nakase H, Ye BD, Chao K, Wu HY, Eccleston J, Yao X, Palac H, Mohamed MF, Ponce-Bobadilla AV, Suravaram S, Barrachina EM, Hisamatsu T, Gao X.   +13 more
europepmc   +1 more source

Upadacitinib Outcomes After Tofacitinib Failure in Patients With Moderate to Severe Ulcerative Colitis. [PDF]

ACG Case Rep J
Pratap K, AlBassam ABA, Narula N.
europepmc   +1 more source

Letter to the Editor: Can upadacitinib dose escalation redefine treatment strategies in refractory inflammatory bowel disease? [PDF]

World J Gastrointest Pharmacol Ther
Agrawal H, Gupta N.
europepmc   +1 more source

Successful treatment of Grover's disease with upadacitinib: A case report. [PDF]

SAGE Open Med Case Rep
Arora E, Oosterhuis R, Sutherland AE.
europepmc   +1 more source